Dashboard
Manage Tickers

CNTACentessa Pharmaceuticals plc

Nasdaq centessa.com


$ 12.83 $ 0.65 (5.33 %)    

Friday, 23-Aug-2024 15:59:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 12.85
$ 12.21
$ 12.82 x 100
-- x --
$ 12.00 - $ 12.91
$ 5.15 - $ 13.56
878,867
na
1.34B
$ 0.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oppenheimer-reiterates-outperform-on-centessa-pharmaceuticals-maintains-14-price-target
Oppenheimer Reiterates Outperform on Cente...
08/14/2024 17:38:29

Oppenheimer analyst Francois Brisebois reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $14...

centessa-pharmaceuticals-q2-2024-gaap-eps-040-misses-039-estimate
Centessa Pharmaceuticals Q2 2024 GAAP EPS ...
08/13/2024 11:08:13

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estima...

oppenheimer-initiates-coverage-on-centessa-pharmaceuticals-with-outperform-rating-announces-price-target-of-14
Oppenheimer Initiates Coverage On Centessa...
07/18/2024 12:50:55

Oppenheimer analyst Francois Brisebois initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating...

morgan-stanley-maintains-equal-weight-on-centessa-pharmaceuticals-raises-price-target-to-11
Morgan Stanley Maintains Equal-Weight on C...
06/21/2024 14:14:07

Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Equal-Weight and raises the ...

centessa-pharma-taps-john-crowley-as-cfo-effective-june-10
Centessa Pharma Taps John Crowley, as CFO,...
06/10/2024 11:20:39

 Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicine...

reported-earlier-centessa-pharmaceuticals-prices-100m-public-offering-of-10810810-american-depositary-shares-at-925ads
Reported Earlier, Centessa Pharmaceuticals...
04/24/2024 06:18:39

announces-100m-proposed-public-offering-of-american-depositary-shares
Announces $100M Proposed Public Offering O...
04/23/2024 20:18:36

the-fda-has-cleared-centessa-pharmaceuticals-investigational-new-drug-application-to-initiate-a-phase-1-first-in-human-clinical-trial-of-orx750-for-narcolepsy
The FDA Has Cleared Centessa Pharmaceutica...
04/22/2024 11:09:07

bmo-capital-maintains-outperform-on-centessa-pharmaceuticals-maintains-15-price-target
BMO Capital Maintains Outperform on Centes...
04/01/2024 16:25:57

BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 pr...

centessa-pharmaceuticals-q4-eps-038-beats-048-estimate
Centessa Pharmaceuticals Q4 EPS $(0.38) Be...
03/28/2024 20:56:31

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate...

why-take-two-interactive-software-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Take-Two Interactive Software Shares A...
02/09/2024 18:18:14

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter res...

sps-commerce-posts-upbeat-results-joins-masonite-international-impinj-and-other-big-stocks-moving-higher-on-friday
SPS Commerce Posts Upbeat Results, Joins M...
02/09/2024 15:31:44

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ...

centessa-pharmaceuticals-to-present-additional-52-weeks-continuous-treatment-data-from-third-year-ongoing-phase-2a-study-of-serpinpc-for-treatment-of-hemophilia-at-17th-annual-congress-of-european-association-for-haemophilia-and-allied-disorders
Centessa Pharmaceuticals To Present Additi...
02/09/2024 12:09:18

centessa-pharmaceuticals-announced-new-data-from-additional-52-weeks-of-continuous-treatment-from-third-year-part-5-of-ongoing-phase-2a-study-of-serpinpc-for-treatment-of-hemophilia-at-2023-ash-meeting
Centessa Pharmaceuticals Announced New Dat...
12/10/2023 17:57:16

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from t...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/27/2023 21:31:02

Core News & Articles
Anaptys Expands Immune Cell Modulator Pipe...
11/27/2023 21:16:34

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfol...

jefferies-upgrades-centessa-pharmaceuticals-to-buy-raises-price-target-to-11
Jefferies Upgrades Centessa Pharmaceutical...
11/15/2023 11:23:13

Jefferies analyst Kelly Shi upgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Hold to Buy and raises the price target fro...

centessa-pharmaceuticals-q3-eps-040-beats-052-estimate
Centessa Pharmaceuticals Q3 EPS $(0.40) Be...
11/13/2023 22:35:55

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate...

centessa-pharmaceuticals-had-cash-cash-equivalents-and-short-term-investments-of-2813m-as-of-sept-30
Centessa Pharmaceuticals Had Cash, Cash Eq...
11/13/2023 22:15:24

centessa-pharmaceuticals-to-present-additional-52-weeks-of-continuous-treatment-data-from-third-year-of-ongoing-phase-2a-study-of-serpinpc-for-the-treatment-of-hemophilia-at-ash-annual-meeting
Centessa Pharmaceuticals To Present Additi...
11/02/2023 13:12:19

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION